Due to compromised homologous recombination (
HR
) repair,
BRCA
1‐
and
BRCA
2‐
mutated tumours accumulate
DNA
damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically
BRCA
2‐deficient cells, we screened a chemical library containing compounds in clinical use. The top hit was chlorambucil, a bifunctional alkylating agent used for the treatment of chronic lymphocytic leukaemia (
CLL
). We establish that chlorambucil is specifically toxic to
BRCA
1/2‐deficient cells, including olaparib‐resistant and cisplatin‐resistant ones, suggesting the potential clinical use of chlorambucil against disease which has become resistant to these drugs. Additionally, chlorambucil eradicates
BRCA
2‐deficient xenografts and inhibits growth of olaparib‐resistant patient‐derived tumour xenografts (
PDTX
s). We demonstrate that chlorambucil inflicts replication‐associated
DNA
double‐strand breaks (
DSB
s), similarly to cisplatin, and we identify
ATR
,
FANCD
2 and the
SNM
1A nuclease as determinants of sensitivity to both drugs. Importantly, chlorambucil is substantially less toxic to normal cells and tissues
in vitro
and
in vivo
relative to cisplatin. Because chlorambucil and cisplatin are equally effective inhibitors of
BRCA
2‐compromised tumours, our results indicate that chlorambucil has a higher therapeutic index than cisplatin in targeting
BRCA
‐deficient tumours.